- Home
- AVTX vs AGD Comparison
AVTX vs AGD Comparison
Compare AVTX & AGD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AVTX | AGD |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 328.4M | 329.6M |
| IPO Year | 2015 | 2006 |
Fundamental Metrics
Financial Performance| Metric | AVTX | AGD |
|---|---|---|
| Price | $17.76 | $11.93 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $40.57 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 111.0K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.07 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,813,137.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2312.27 | N/A |
| 52 Week Low | $4.73 | $10.41 |
| 52 Week High | $24.27 | $13.98 |
Technical Indicators
Market Signals| Indicator | AVTX | AGD |
|---|---|---|
| Relative Strength Index (RSI) | 64.69 | 40.45 |
| Support Level | $13.13 | $11.24 |
| Resistance Level | $19.06 | $12.31 |
| Average True Range (ATR) | 1.06 | 0.23 |
| MACD | 0.55 | -0.05 |
| Stochastic Oscillator | 92.22 | 5.00 |
Price Performance
Historical ComparisonAbout AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
About AGD abrdn Global Dynamic Dividend Fund of Beneficial Interest
Aberdeen Global Dynamic Dividend Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current dividend income, more than 50% of which qualifies for the reduced federal income tax rate, as created by the Jobs and Growth Tax Relief Reconciliation Act of 2003. The fund also focuses on the long-term growth of capital as a secondary investment objective. The fund's portfolio holdings are in information technology, financials, health care, and consumer discretionary sectors, among others.